Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Aryl Hydrocarbon Receptor Ligands Drive Pancreatic Cancer Initiation and Progression through Protumorigenic T-cell Polarization.

  PMID 40905825 · PMC12793834 · Cancer discovery · 2026 · 8 claims · 8 setups

  Full-text index only

  AHR ligands (cigarette smoke extract and TCDD) promote PDAC tumor growth in a syngeneic orthotopic mouse model

  pdac naïve il22 orthotopic naïve western

• Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome.

  PMID 41956098 · PMC7619149 · Immunity · 2026 · 8 claims · 8 setups

  Full-text index only

  Reduced NMD activity (lower NMD score) predicts improved CPI response across >1,000 patients, independent of TMB or tumor type

  tcga a375 reporter patient-derived multi-omics crispr-cas9 sirna

• CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance.

  PMID 41564866 · PMC12866162 · Cell reports. Medicine · 2026 · 8 claims · 8 setups

  Full-text index only

  CHD1 and MAP3K7 loss additively sensitizes cancer cells to IFN-γ-induced death

  a375 crc-9 ht-29 vcap whole-genome autologous incucyte

• 5-HT reuptake blockade induces pyroptosis in BRAF(V600E)-mutated melanomas via remodeling histone serotonylation.

  PMID 41494533 · PMC12866116 · Cell reports. Medicine · 2026 · 8 claims · 8 setups

  Has reproduction · 40

  High-throughput screening of 90 FDA-approved antidepressants identifies PH as an alternative therapeutic for BRAF V600E-mutated melanoma

  braf a375 gfp-tph1-overexpressing yumm1.7 high-throughput ic50 xenograft

• Proteomic and genetic approaches identify Syk as an AML target.

  PMID 19800574 · PMC2803063 · Cancer cell · 2009 · 8 claims · 8 setups

  Full-text index only

  EGFR inhibitors (e.g., gefitinib) induce AML differentiation through a non-EGFR, off-target mechanism

  hl-60 aml molm-14 luciferase-labeled phospho-tyrosine kinome-wide secondary